FrancophonIA/ELRC3.0 huggingface dataset:
English: It is used in adults who are overweight with a body mass index (BMI) greater than or equal to 28 kg per square metre, in combination with a low calorie diet with reduced fat levels.
Estonian: Allit kasutatakse ülekaalulistel täiskasvanud patsientidel, kelle kehamassiindeks on vähemalt 28 kg/m², koos kalorivaese ja vähese rasvasisaldusega dieediga.
English: How is Alli used?
Estonian: Kuidas Allit kasutatakse?
English: What is Alli used for?
Estonian: Milleks Allit kasutatakse?
English: Alli was more effective than placebo in reducing weight in patients with a BMI of 28 kg/m2 or more.
Estonian: Alli oli vähemalt 28 mg/m2 kehamassiindeksiga patsientide kehakaalu vähendamisel efektiivsem kui platseebo.
English: • under 18 years old;
Estonian: • alla 18-aastased patsiendid,
English: Osigraft must also not be used by the following groups of patients:
Estonian: Osigrafti ei tohi kasutada ka järgmistes patsiendirühmades:
English: The European Commission granted a marketing authorisation valid throughout the European Union for Osigraft to Howmedica International S. de R. L. on 17 May 2001.
Estonian: Euroopa Komisjon andis müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Howmedica International S. de R. L. 17. mail 2001.
English: The full EPAR for Osigraft can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Osigrafti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Generally, one vial is sufficient, but a further vial can be used if necessary.
Estonian: Enamasti piisab ühest ravimiviaalist, kuid vajadusel võib kasutada ka kahte.
English: • with an autoimmune disease (where the immune system attacks parts of the body);
Estonian: • autoimmuunhaigusega patsiendid (kui immuunsüsteem ründab organismi osi),
English: Other information about Osigraft
Estonian: Muu teave Osigrafti kohta
English: The most common side effects with Osigraft (seen in between 1 and 10 patients in 100) are erythema (redness), tenderness, swelling over the implant site, heterotopic ossification (development of bone in abnormal areas) or myositis ossificans (abnormal bone growth in the muscle), and the formation of antibodies against eptotermin alfa.
Estonian: Osigrafti kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on erüteem (punetus), hellus, paigalduskoha paistetus ja heterotoopne luustumine (luukoe teke muudes kohtades kui luukoes) või myositis ossificans (luukoe ebanormaalne kasv lihasesse) ja alfaeptotermiini vastaste antikehade teke.
English: Osigraft should be used by a qualified surgeon.
Estonian: Osigrafti võib kasutada üksnes kvalifitseeritud kirurg.
English: It is a copy of a protein called osteogenic protein 1, also known as bone morphogenetic protein 7 (BMP-7), that is produced naturally by the body and which helps the formation of new bone tissue.
Estonian: See on sellise valgu koopia, mida nimetatakse osteogeenne proteiin 1 või luu morfogeneetiline proteiin 7 (BMP-7), see tekib organismis loomulikul viisil ning aitab tekitada uut luukude.
English: • with an active infection at the surgery site or another serious infection;
Estonian: • operatsioonikoha aktiivse nakkusega või teiste raskete nakkustega patsiendid,
English: After nine months, 81% of the patients receiving Osigraft had responded to treatment (less pain and more weight bearing), compared with 77% of the patients treated with an autograft.
Estonian: Üheksa kuu pärast oli ravile reageerinud (väiksem valu ja parem jalale toetumise võime) 81% Osigrafti saanud patsientidest ning 77% luusiirikuga ravitud patsientidest.
English: The CHMP decided that Osigraft's benefits are greater than its risks and recommended that Osigraft be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Osigrafti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: For more information about treatment with Osigraft, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Osigraftiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It is used in patients who have previously had an autograft (a bone graft taken from their own bone, usually the hip) that has failed or when such a graft is not possible.
Estonian: Seda kasutatakse patsientidel, kellele varem oli siirdatud omasiirik (luusiirik, mis on valmistatud patsiendi enda luukoest, mis enamasti on võetud puusapiirkonnast) ja see ebaõnnestus või kellel omasiirikut ei ole võimalik kasutada.
English: Osigraft is a powder to be made up into a suspension for implantation.
Estonian: Osigraft on pulber, millest valmistatakse siirdamisel kasutatav suspensioon.
English: Osigraft should not be used in people who may be hypersensitive (allergic) to eptotermin alfa or to collagen.
Estonian: Osigrafti ei tohi kasutada patsientidel, kes võivad olla alfaeptotermiini või kollageeni suhtes ülitundlikud (allergilised).
English: Osigraft was at least as effective as bone autograft, the standard treatment.
Estonian: Osigraft oli vähemalt sama tõhus nagu luusiirik, mille kasutamine on sellisel puhul standardne ravimeetod.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Osigraft.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The replacement eptotermin alfa acts in same way as naturally produced BMP-7.
Estonian: Tehislik alfaeptotermiin toimib samal viisil kui organismis looduslikult tekkiv BMP-7.
English: Immediately before use, Osigraft is mixed with 2 to 3 ml of sodium chloride solution to make up a suspension that has the consistency of wet sand.
Estonian: Vahetult enne kasutamist segatakse Osigraft 23 ml naatriumkloriidi lahusega, et valmistada märja liiva taolise konsistentsiga suspensioon.
English: Eptotermin alfa is produced by a method known as ‘recombinant DNA technology': it is made by cells that have received a gene (DNA), which makes them able to produce it.
Estonian: Alfaeptotermiini valmistatakse rekombinantDNA-tehnika abil: seda toodavad rakud, millele on lisatud selle tootmist võimaldav geen (DNA).
English: What is the risk associated with Osigraft?
Estonian: Mis riskid Osigraftiga kaasnevad?
English: This mixture is then placed by the surgeon directly at the fracture site in contact with the prepared broken bone ends.
Estonian: Kirurg asetab segu vahetult luumurru kohale, ettevalmistatud luuotstele.
English: • where the fracture is disease-related (such as metabolic bone disease or cancer);
Estonian: • haigusest tingitud murruga patsiendid (murru põhjuseks on näiteks luu ainevahetuse haigus või vähk),
English: Osigraft is used to repair fractures of the tibia (shin bone) that have not healed after at least nine months.
Estonian: Osigrafti kasutatakse selliste sääreluumurdude raviks, mis ei ole paranenud vähemalt üheksa kuu jooksul.
English: It is used in skeletally mature patients (who have stopped growing).
Estonian: Ravimit kasutatakse väljaarenenud luustikuga patsientidel (kelle kasvamine on lõppenud).
English: This was detected by looking at signs of repair of the fracture on an X-ray, whether the patient had any pain and was able to bear weight on the tibia, and whether there was any need for further treatment of the fractured tibia.
Estonian: Paranemise tuvastamiseks uuriti röntgenipildi abil murru paranemise tunnuseid, märgiti, kas patsiendil esineb valu, kas ta saab jalale toetuda ning kas on luumurdu vaja täiendavalt ravida.
English: • with a tumour near the fracture;
Estonian: • patsiendid, kellel on murru koha lähedal kasvaja,
English: Why has Osigraft been approved?
Estonian: Miks Osigraft heaks kiideti?
English: The main measure of effectiveness, which was assessed after nine months, was whether the broken bone had healed.
Estonian: Efektiivsuse põhinäitaja oli murdunud luu paranemine üheksa kuu pärast.
English: What is Osigraft?
Estonian: Mis on Osigraft?
English: • without enough skin or blood supply at the fracture site;
Estonian: • patsiendid, kellel murrukohas ei ole piisavalt nahka või kellel on murrukohas puudulik verevarustus,
English: The main study of Osigraft was carried out in 122 patients with unhealed tibial fractures who were treated either with the medicine or with an autograft.
Estonian: Osigrafti põhiuuring viidi läbi 122-l paranemata sääreluumurruga patsiendil, keda raviti kas Osigrafti või luusiirikuga.
English: For the full list of all side effects reported with Osigraft, see the package leaflet.
Estonian: Osigrafti kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: • receiving chemotherapy, radiation treatment or immunosuppression.
Estonian: • kemoteraapiat, kiiritusravi või immunosupressiivset (immuunsüsteemi pärssivat) ravi saavad patsiendid.
English: It contains the active substance eptotermin alfa.
Estonian: Osigraft sisaldab toimeainena alfaeptotermiini.
English: When implanted, eptotermin alfa stimulates the formation of new bone, helping to repair the broken bone.
Estonian: Murrukohas kasutamisel kiirendab alfaeptotermiin uue luukoe moodustamist, soodustades luumurru paranemist.
English: Osigraft eptotermin alfa
Estonian: Osigraft alfaeptotermiin
English: This is a summary of the European public assessment report (EPAR) for Osigraft.
Estonian: Käesolev dokument on ravimi Osigraft Euroopa avaliku hindamisaruande kokkuvõte.
English: • skeletally immature (still growing);
Estonian: • ebaküpse luustikuga patsiendid (kasv jätkub),
English: The surrounding soft tissues, such as muscle and skin, are then closed around the implant.
Estonian: Seejärel kaetakse siirik ümbritsevate pehmete kudedega, lihaste ja nahaga.
English: What benefit has Osigraft shown during the studies?
Estonian: Milles seisnes uuringute põhjal Osigrafti kasulikkus?
English: The active substance in Osigraft, eptotermin alfa, acts on the bone structure.
Estonian: Osigrafti toimeaine alfaeptotermiin mõjutab luustruktuuri.
English: How is Osigraft used?
Estonian: Kuidas Osigrafti kasutatakse?
English: What is Osigraft used for?
Estonian: Milleks Osigrafti kasutatakse?
English: How does Osigraft work?
Estonian: Kuidas Osigraft toimib?
English: How has Osigraft been studied?
Estonian: Kuidas Osigrafti uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Osigraft on retseptiravim.
English: Where necessary, treatment can be repeated every twelve weeks.
Estonian: Kui on vaja, tohib ravi korrata iga 12 nädala järel.
English: Bravecto Plus received a marketing authorisation valid throughout the EU on 8 May 2018.
Estonian: Bravecto Plusi müügiluba, mis kehtib kogu Euroopa Liidus, anti 8. mail 2018.
English: Further information on Bravecto Plus can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/bravecto-plus.
Estonian: Lisateave Bravecto Plusi kohta on ameti veebilehel: ema.europa.eu/medicines/veterinary/EPAR/bravecto-plus.
English: The medicine should be kept in the original package until use, in order to prevent children directly accessing the medicine.
Estonian: Ravimit tuleb hoida originaalpakendis kuni kasutamiseni, et takistada ravimi sattumist laste kätte.
English: Bravecto Plus kills fleas and ticks within 48 hours.
Estonian: Bravecto Plus surmab kirbud ja puugid 48 tunni jooksul.
English: This medicine is harmful if swallowed.
Estonian: Ravim on allaneelamisel kahjulik.
English: The European Medicines Agency decided that Bravecto Plus's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Bravecto Plusi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise saab Euroopa Liidus heaks kiita.
English: For ear mite infestations, a veterinary check is necessary 28 days after treatment.
Estonian: Kuulmelestainfestatsioonide korral on 28 päeva pärast ravi vaja teha veterinaarkontroll.
English: Bravecto Plus (fluralaner / moxidectin)
Estonian: Bravecto Plus (fluralaneer/moksidektiin)
English: Contact with the application site should be avoided until it is no longer noticeable.
Estonian: Kokkupuudet manustamiskohaga peab vältima seni, kuni see on veel nähtav.
English: What is Bravecto Plus and what is it used for?
Estonian: Mis on Bravecto Plus ja milleks seda kasutatakse?
English: Other information about Bravecto Plus
Estonian: Muu teave Bravecto Plusi kohta
English: Bravecto Plus is effective at preventing heartworm disease for 8 weeks.
Estonian: Bravecto Plus on südameusstõve ennetamisel efektiivne 8 nädalat.
English: Bravecto Plus spot-on solution should be kept away from heat, sparks, open flames or other fire sources as it is highly flammable.
Estonian: Bravecto Plusi täpilahust tuleb hoida eemal soojusallikast, sädemetest, lahtisest leegist või muudest süttimisallikatest, sest see on eriti tuleohtlik.
English: It can also be used as part of a treatment for flea allergy dermatitis (an allergic reaction to flea bites)
Estonian: ravimit tohib kasutada ka kirbuallergiast tingitud dermatiidi (allergiline reaktsioon kirbuhammustustele) ravi osana;
English: The medicine's actions against fleas and ticks last for 12 weeks after being applied.
Estonian: Ravimi kirbu- ja puugivastane toime kestab pärast pealekandmist 12 nädalat.
English: The most common side effects with Bravecto Plus (which may affect up to 1 in 10 animals) are mild and short-lived reactions at the application site such as hair loss, flaking skin and scratching.
Estonian: Bravecto Plusi kõige sagedamad kõrvalnähud (võivad esineda kuni 1 loomal 10st) on kerged ja lühiajalised manustamiskoha reaktsioonid, nt karvakadu, nahaketendus ja kratsimine.
English: Bravecto Plus was as effective as another medicine containing emodepside and praziquantel.
Estonian: Bravecto Plus oli sama efektiivne kui teine ravim, mis sisaldas emodepsiidi ja prasikvanteeli.
English: Fluralaner and moxidectin are already authorised on their own for the treatment of parasitic infestations.
Estonian: Fluralaneer ja moksidektiin on parasitaarsete nakkuste raviks eraldi juba heaks kiidetud.
English: In order to be exposed to the active substance fluralaner, fleas and ticks must commence feeding on the cat.
Estonian: Toimeaine fluralaneeriga kokkupuutumiseks peavad kirbud ja puugid alustama kassi verest toitumist.
English: In case of spillage on table or floor surfaces, excess Bravecto Plus spot-on solution should be removed using paper tissue and the area cleaned with a detergent.
Estonian: Lauale või põrandale pillamisel tuleb Bravecto Plusi täpilahuse jäägid eemaldada pabersalvrätiga ja pind puhastada puhastusainega.
English: What are the risks associated with Bravecto Plus?
Estonian: Mis riskid Bravecto Plusiga kaasnevad?
English: Fluralaner kills fleas and ticks that have ingested the cat's blood by causing uncontrolled activity of their nervous system.
Estonian: Fluralaneer surmab kassi verd imenud kirbud ja puugid, põhjustades nende närvisüsteemi kontrollimatut aktiivsust.
English: Fluralaner acts as an ‘ectoparasiticide'.
Estonian: Fluralaneer toimib ektoparasititsiidina.
English: The spot-on solution is available in different strengths for cats of different weights.
Estonian: Täpilahust turustatakse eri tugevuses eri kehamassiga kassidele.
English: Bravecto Plus is a veterinary medicine used in cats to treat mixed infestations with both ticks or fleas and ear mites and/or worms that live inside the body.
Estonian: Bravecto Plus on veterinaarravim, mida kasutatakse kassidel selliste segainfestatsioonide raviks, mida põhjustavad puugid või kirbud ning kuulmelestad ja/või organismis elavad ussid.
English: Two laboratory studies involving healthy cats which were artificially infected with heartworm larvae showed Bravecto Plus to be 100% effective in preventing heartworm disease during 8 weeks.
Estonian: Kahes laboratoorses teadusuuringus, milles uuriti terveid kasse, keda oli nakatatud südameussidega, tõendati, et Bravecto Plus oli südameusstõve ennetamisel 8 nädala jooksul 100% efektiivne.
English: An overview of Bravecto Plus and why it is authorised in the EU
Estonian: Bravecto Plusi ülevaade ja Euroopa Liidus heakskiitmise põhjused
English: In a field study of 167 cats infested with 5 or more ear mites, treatment with Bravecto Plus resulted in 94% of cats free from ear mites 14 days after treatment and 100% of cats free from ear mites 28 days after treatment.
Estonian: Väliuuringus, milles 167 kassi nakatati vähemalt 5 kuulmelestaga, olid kassidest Bravecto Plusi ravi tulemusel ilma kuulmelestadeta 14 päeva pärast ravi 94% ja 28 päeva pärast ravi 100%.
English: For the full list of side effects and restrictions of Bravecto Plus, see the package leaflet.
Estonian: Bravecto Plusi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: • to prevent heartworm disease Bravecto Plus must only be used when there is a need to treat ticks or fleas and one or more of the parasites listed above.
Estonian: Bravecto Plusi tohib kasutada ainult juhul, kui on looma vaja ravida puukide või kirpude ja ühe või mitme eespool nimetatud parasiidi tõttu.
English: A field study involving cats naturally infested with ticks and/or fleas showed treatment with Bravecto Plus to reduce tick and flea counts by more than 95% and to be as effective as treatment using fipronil, another medicine already licensed for the treatment of ticks and fleas.
Estonian: Väliuuringus, milles uuriti looduslikult puukide ja/või kirpudega nakatunud kasse, tõendati, et ravi Bravecto Plusiga vähendas puukide ja kirpude arvu üle 95% võrra ning see oli sama efektiivne kui puukide ja kirpude raviks juba heaks kiidetud teine ravim fiproniil.
English: Fluralaner kills fleas before they can lay eggs and so helps to reduce contamination of the cats' environment.
Estonian: Fluralaneer hävitab kirbud, enne kui nad jõuavad muneda, mis aitab vähendada parasiitide levimist kassi ümbrusesse.
English: The content of one full Bravecto Plus pipette is applied to the cat's skin at the base of the skull.
Estonian: Ühe täis Bravecto Plusi pipeti sisu kantakse kassi nahale kuklapiirkonda.
English: For more information about using Bravecto Plus, see the package leaflet or contact your veterinarian or pharmacist.
Estonian: Kui vajate Bravecto Plusiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte või pöörduge oma veterinaararsti või apteekri poole.
English: The pipette to use is selected on the basis of the cat's weight.
Estonian: Kasutatav pipett valitakse kassi kehamassi järgi.
English: Bravecto Plus contains the active substances fluralaner and moxidectin.
Estonian: Bravecto Plus sisaldab toimeainena fluralaneeri ja moksidektiini.
English: This results in paralysis and death of the parasites.
Estonian: Fluralaneer põhjustab parasiitide halvatuse ja surma.
English: In case of skin contact, the affected area should be rinsed immediately with soap and water whilst in case of eye contact, the affected area should be rinsed immediately with water.
Estonian: Kui ravimit satub nahale, tuleb kokkupuutekohta viivitamatult pesta vee ja seebiga; kui ravimit satub silma, tuleb silma viivitamata pesta veega.
English: Bravecto Plus was as effective as selamectin, another medicine already licensed for the treatment of ear mites in cats.
Estonian: Bravecto Plus oli sama efektiivne kui kuulmelestade raviks kassidel juba heaks kiidetud teine ravim selamektiin.
English: Another field study involving cats naturally infected with roundworms and/or hookworms showed treatment with Bravecto Plus to reduce faecal egg counts by 100%.
Estonian: Teises väliuuringus, milles uuriti looduslikult ümarusside ja/või kidakärssussidega nakatunud kasse, tõendati, et ravi Bravecto Plusiga vähendas ussnugiliste munade eritamist roojaga 100%.
English: How does Bravecto Plus work?
Estonian: Kuidas Bravecto Plus toimib?
English: How is Bravecto Plus used?
Estonian: Kuidas Bravecto Plusi kasutatakse?
English: This means that it kills parasites present on the skin or in the fur or ears of animals, such as fleas, ticks and ear mites.
Estonian: See tähendab, et ravim hävitab parasiite, kes elavad loomade nahal või karvades, nt kirbud või puugid.
English: Moxidectin causes paralysis and death of these parasites by interfering with the way signals are passed between nerve cells (neurotransmission) in the parasites' nervous system.
Estonian: Moksidektiin mõjutab parasiitide närvisüsteemis neurotransmissiooni (signaalide edastamist närvirakkude vahel), põhjustades parasiitide halvatust ja surma.
English: Bravecto Plus is available as a spot-on solution in a pipette.
Estonian: Bravecto Plusi turustatakse täpilahusena pipetis.
English: If skin reactions occur, the advice of a doctor should be sought immediately and the package leaflet or label shown to the doctor.
Estonian: Nahareaktsiooni tekke korral tuleb nõu saamiseks kohe pöörduda arsti poole ja näidata talle pakendi infolehte või etiketti.
English: Suitable gloves should be worn when handling or applying Bravecto Plus to cats.
Estonian: Bravecto Plusi käsitsemise või kassile pealekandmise ajal peab kandma kaitsekindaid.
English: Moxidectin kills parasites present in the body of animals such as roundworms, hookworms and heartworm as well as ear mites.
Estonian: Moksidektiin surmab looma organismis esinevad parasiidid, nt ümarussid, kidakärssussid ja südameussid ning kuulmelestad.
English: The active substances in Bravecto Plus, fluralaner and moxidectin, work via different routes to kill parasites.
Estonian: Bravecto Plusi toimeained fluralaneer ja moksidektiin surmavad parasiite erinevate toimemehhanismide abil.
English: Skin rashes, tingling or numbness have been reported in a small number of individuals after skin contact, either when handling the product or when handling the treated animal.
Estonian: Pärast ravimi käsitsemist või ravitud looma katsumisel tekkinud nahakontakti on väike arv inimestest teatanud nahalööbe, surisemistunde või tuimuse esinemisest.
English: What benefits of Bravecto Plus have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Bravecto Plusi kasulikkus?
English: • to treat flea infestations.
Estonian: • kirbuinfestatsioonide raviks.
English: • to treat roundworms and hookworms in the gut
Estonian: • soolestiku ümarusside ja kidakärssusside raviks;
English: Why is Bravecto Plus authorised in the EU?
Estonian: Bravecto Plusi Euroopa Liidus heakskiitmise põhjused
English: • to treat ear mite infestations
Estonian: • kuulmelestainfestatsioonide raviks;
English: The medicine can only be obtained with a prescription.
Estonian: Bravecto Plus on retseptiravim.
English: No new substantial data were submitted.
Estonian: Uusi olulisi andmeid ei esitatud.
English: SCIENTIFIC CONCLUSIONS 1.
Estonian: TEADUSLIKUD JÄRELDUSED 1.
English: 2.5 Advice to doctors
Estonian: 2.5 Nõuanne arstidele
English: 2.4 Risks for pregnant women
Estonian: 2.4 Ohud rasedatele
English: This is considered to be the appropriate way of expressing such an advice to doctors.
Estonian: Seetõttu peeti seda ka sobivaks viisiks taolise nõuande andmiseks arstidele.
English: Tijdsch.for Diergeneeskunde deel 131 Maart aflevering 6 2006.
Estonian: Tijdsch.for Diergeneeskunde deel 131 Maart atlevring 6 2006.
English: Pregnant women should not handle the product.
Estonian: Rasedad ei tohi seda ravimit käsitseda.
English: The safety of Precedex during labour and delivery has not been studied.
Estonian: Precedexi ohutust sünnitegevuse ja sünnituse ajal ei ole uuritud.
English: The proposed precautionary measures relate to different user safety concerns.
Estonian: Pakutud ettevaatusabinõud on seotud mitme kasutajaohutuse probleemiga.
English: There are no adequate and well-controlled studies in pregnant women.
Estonian: Adekvaatseid ja hästikontrollitud uuringuid rasedatel ei ole tehtud.
English: NL Sedazine 20 Inj.
Estonian: Madalmaad Sedazine 20 Inj.